Genetic changes known asKRAS mutations are frequently observed in pancreatic cancer cellsand are linked to poor prognosis and treatment resistance.26 KRAS mutations in ctDNA have been identifiedas a promising novel biomarker for advanced pancreatic cancer, enablingnoninvasive surveillance of the disease’s course and therapeuticresponse. Here, KRAS is linked to familial pancreatic carcinoma.